Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal

The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...
Pharmaceutical Technology

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
MedPage Today on MSN

Real-world registry study shows Alzheimer's drug safety outcomes

No new signals for lecanemab emerged in ALZ-NET ...
MedPage Today on MSN

Cell therapy slows upper limb decline in Duchenne muscular dystrophy

Investigational deramiocel is back under FDA review again ...

Jim Cramer Says “I Got to Reopen the File on Biogen”

Well, I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams. including Alzheimer’s, and it ...

UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?

Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...

Jim Cramer’s 17 Stock Calls: Applied Materials and CoreWeave

In this article, we will look at Jim Cramer’s stock calls on Mad Money recently. The host of Mad Money said Monday that the ...
Stocks Telegraph

Biogen Inc. (BIIB) Receives Buy Rating from UBS Analysts, Target Raised to $225

Biogen Inc. (NASDAQ: BIIB) has recently been upgraded to a “Buy” rating by UBS analyst Michael Yee, with a new price target set at $225, signaling strong upside potential from the current trading ...
24/7 Wall St.

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and M…

Futures are trading higher as we hit the midweek point. All major indices finished lower on Tuesday as the deadline for the ...

This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce

The investment bank upgraded the pharmaceutical name to buy from neutral. It also hiked its price target on shares to $225 ...
BioWorld

Biogen amasses full felzartamab rights with $850M TJ deal

Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April ...